Chromadex (NASDAQ:CDXC) posted its quarterly earnings data on Tuesday. The company reported ($0.12) EPS for the quarter, hitting analysts’ consensus estimates of ($0.12), Bloomberg Earnings reports. The firm had revenue of $12.05 million during the quarter, compared to analysts’ expectations of $11.66 million. Chromadex had a negative return on equity of 147.85% and a negative net margin of 74.55%.
Shares of NASDAQ CDXC traded up $0.16 during midday trading on Friday, hitting $3.24. The stock had a trading volume of 15,416 shares, compared to its average volume of 252,506. The company has a market capitalization of $168.57 million, a price-to-earnings ratio of -5.38 and a beta of 1.35. Chromadex has a 1-year low of $2.68 and a 1-year high of $4.95. The company has a quick ratio of 1.11, a current ratio of 1.55 and a debt-to-equity ratio of 0.09. The company has a fifty day moving average price of $3.31 and a 200 day moving average price of $4.05.
CDXC has been the subject of a number of recent research reports. ValuEngine cut Chromadex from a “buy” rating to a “hold” rating in a research report on Tuesday, October 1st. Oppenheimer initiated coverage on Chromadex in a research report on Tuesday, October 15th. They set an “outperform” rating and a $6.00 price objective for the company. Finally, Zacks Investment Research upgraded Chromadex from a “sell” rating to a “hold” rating in a research report on Tuesday, August 13th. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $6.00.
ChromaDex Corporation operates as a nutraceutical company. The company offers Nicotinamide riboside (NIAGEN), a novel form of vitamin B3 for enhancing nicotinamide adenine dinucleotide (NAD) level used for healthy aging; and Immulina, a spirulina extract and compound, which is used for improving human immune function.
See Also: Inverted Yield Curve
Receive News & Ratings for Chromadex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chromadex and related companies with MarketBeat.com's FREE daily email newsletter.